Previous Close | 0.0100 |
Open | 0.0100 |
Bid | 0.0100 x N/A |
Ask | 0.0150 x N/A |
Day's Range | 0.0100 - 0.0100 |
52 Week Range | 0.0050 - 0.0800 |
Volume | |
Avg. Volume | 210,897 |
Market Cap | 1.034M |
Beta (5Y Monthly) | 3.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4290 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
VANCOUVER, British Columbia, June 19, 2023--Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. ("KGK" or the "Subsidiary"), will participate at the upcoming Mushroom Summit, t
VANCOUVER, British Columbia, June 16, 2023--Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that the Company has entered into a share purchase agreement (the "Purchase Agreement"), dated June 7, 2023, with Cardinal Group In
VANCOUVER, British Columbia, May 25, 2023--Wellbeing Digital Sciences Inc. ("Wellbeing" or the "Company") (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its subsidiary KGK Science Inc. ("KGK" or the "Subsidiary") will participate at the upcoming Nutrition Industry Association ("N